RxDoctor Payments DataLook up a doctor →

William Sanders, MD

Family Medicine · Ruston, LANPI 1093921066

Payments from drug & device makers

$16,379in general payments, 2019–2025

Across 1,011 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Lilly USA, LLC$1K
  • Bayer$918
  • Pfizer$847
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$16,348100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)87$1,925
Novo Nordisk97$1,412
Takeda Pharmaceuticals U.S.A., Inc.82$1,278
Lilly USA, LLC90$1,197
Bayer53$918
Pfizer58$847
Amgen49$758
Boehringer Ingelheim47$744
Acadia Pharmaceuticals Inc56$628
AbbVie(2 entities)51$612
GSK36$583
Merck34$533
Astellas Pharma US Inc25$400
Lundbeck LLC19$388
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC23$335
Otsuka America Pharmaceutical, Inc.15$307
Sumitomo Pharma America, Inc.12$264
Kowa Pharmaceuticals America, Inc.17$259
Phathom Pharmaceuticals, Inc.14$245
Supernus Pharmaceuticals, Inc.5$211
Ironshore Pharmaceuticals Inc.9$193
Biohaven Pharmaceutical Holding Company Ltd.9$193
Biohaven Pharmaceuticals, Inc.11$190
Esperion Therapeutics, Inc.12$176
Johnson & Johnson10$153
Idorsia Pharmaceuticals US Inc7$120
Axsome Therapeutics, Inc.5$111
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$111
Abbott4$82
Stryker1$73
Collegium Pharmaceutical, Inc.4$70
Teva Pharmaceuticals USA, Inc.5$66
Sunovion Pharmaceuticals Inc.6$64
Shire North American Group Inc3$61
Vanda Pharmaceuticals Inc.3$60
Corium, LLC3$53
Tris Pharma Inc3$52
Exact Sciences3$49
Eisai Inc.3$49
Dexcom, Inc.2$48
Novartis3$47
Sanofi-aventis U.S. LLC3$44
Ardelyx, Inc.2$43
Avanir Pharmaceuticals, Inc.2$40
Corcept Therapeutics2$34
Amarin Pharma, Inc.2$29
Mylan Specialty L.p.1$28
ARS Pharmaceuticals Operations, Inc.1$27
Xeris Pharmaceuticals, Inc.1$23
Boston Scientific1$23
Abiomed1$22
Sanofi1$22
Inspire Medical Systems, Inc.1$20
IBSA Pharma Inc.1$20
Jazz Pharmaceuticals Inc.1$18
Ironwood Pharmaceuticals, Inc1$16
Genentech USA, Inc.1$16
Philips North America LLC1$15
Adlon Therapeutics L.p.1$14
Neos Therapeutics, LP1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,379 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$198,940
Medicare patients
596
Services billed
3,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol223$173,918
MounjaroTirzepatide156$169,318
OzempicSemaglutide140$140,451
TrulicityDulaglutide143$139,565
EliquisApixaban134$97,606
Trelegy ElliptaFluticasone/Umeclidin/Vilanter104$84,694
JardianceEmpagliflozin101$83,557
KerendiaFinerenone44$43,488
RybelsusSemaglutide25$37,784
LinzessLinaclotide38$35,935
MyrbetriqMirabegron42$27,693
JanuviaSitagliptin Phosphate36$25,378
XareltoRivaroxaban21$24,039
Breo ElliptaFluticasone/Vilanterol44$21,902
Tresiba Flextouch U-200Insulin Degludec24$20,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,197$308,882299 claims
Novo NordiskOzempic, Rybelsus$1,412$178,236165 claims
AstraZenecaFarxiga$1,925$173,918223 claims
GSKTrelegy Ellipta, Breo Ellipta$583$106,596148 claims
PfizerEliquis$847$97,606134 claims
Boehringer IngelheimJardiance$744$83,557101 claims
BayerKerendia$918$43,48844 claims
AbbVieLinzess, Synthroid$612$40,01698 claims
MerckJanuvia, Belsomra, Janumet Xr$533$37,94967 claims
Johnson & JohnsonXarelto, Concerta$153$29,11734 claims
Astellas Pharma US IncMyrbetriq$400$27,69342 claims
Avanir Pharmaceuticals, Inc.Nuedexta$40$13,32117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Ruston

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →